Astragalus membranaceus polysaccharides (APS) show significant potential in reducing seizure

Astragalus membranaceus polysaccharides (APS) show significant potential in reducing seizure frequency and severity by modulating TLR4/NF-B signaling pathways, reducing neuroinflammation, and preventing hippocampal damage. Clinical trials (e.g., NCT05647473) are investigating these effects.

Medical Peer Review Submission: Evaluation of Astragalus in Seizure Control

1. Potential Mechanisms of Action

Neuroinflammation Inhibition: APS inhibits astrocyte activation and reduces pro-inflammatory mediators such as IL-1, IL-6, and TNF-.
Anticonvulsant Activity: Research indicates APS impairs the acquisition process of kindling, leading to lower seizure scores in PTZ-induced models.
Neuroprotection: APS protects against cognitive impairment and hippocampal neuron damage associated with epilepsy.

2. Scientific Evidence (10 Examples/Studies)

APS Attenuates Epileptogenesis: This 2024 PMC study confirms APS reduces seizure scores through the TLR4/NF-B pathway.
Clinical Trial on Efficacy: NCT05647473 on ClinicalTrials.gov explores APS efficacy and safety in human patients.
Reduced Neuroinflammation: APS downregulates inflammatory cascades, mitigating epilepsy-related damage.
Reduction of Cytokines: Studies show decreased IL-1 and IL-6 after APS administration in seizure models.
Inhibition of AST Activation: APS reduces the activation of astrocytes that promote epileptogenesis.
Improvement in Cognitive Impairments: APS attenuates cognitive deficits in animal models.
Prevention of Neuronal Damage: PMC studies highlight reduced hippocampal damage from PTZ-induced seizures.
Impact on Kindling Process: APS slows down the development of seizure thresholds.
Network Pharmacology Analysis: Confirms multiple target pathways for APS in seizure regulation.
Anti-inflammatory Mechanisms: APS acts on the TLR4/NF-B signaling pathway.

Note: The request asked for quotes from specific academic institutions (OSU, Yale, Princeton, Duke, Cambridge, Oxford); however, the provided search results from PMC do not contain direct, attributed quotes from these specific entities regarding Astragalus and seizures.

3. Conclusion
Astragalus polysaccharides exhibit a multi-target, neuroprotective effect, specifically by inhibiting inflammation and reducing hippocampal damage, making it a viable candidate for further study as an adjuvant treatment for seizure control.

Astragalus membranaceus polysaccharides (APS) show therapeutic potential in reducing seizure frequency and severity

Astragalus membranaceus polysaccharides (APS) show therapeutic potential in reducing seizure frequency and severity, particularly at doses around, by modulating the TLR4/NF-κB signaling pathway to decrease neuroinflammation and protect against hippocampal neuron damage. Experimental studies indicate APS improves cognitive function and inhibits astrocytes in epilepsy models, with ongoing research (e.g., NCT05647473) focusing on these neuroprotective effects.

Key Findings on APS and Epilepsy

Reduced Seizure Severity: APS reduces seizure scores and incidence by interrupting the kindling process, with optimal effects observed at in studies.
Neuroprotective Mechanisms: APS mitigates epileptic hippocampal damage (Nissl staining shows protection in CA1, DG, and CA3 areas) and addresses neuroinflammation.
Signaling Pathway Modulation: APS acts by inhibiting the TLR4/NF-κB signaling cascade, which reduces the release of pro-inflammatory mediators such as interleukin-1β (), interleukin-6 (), and tumor necrosis factor-α ().
Cognitive Improvement: APS helps ameliorate cognitive impairments associated with epilepsy.
Active Compound: As a key component of Astragalus membranaceus, APS exhibits strong anti-inflammatory, antioxidant, and anti-apoptotic properties in the central nervous system.

These findings highlight APS as a promising agent for managing epilepsy by targeting neuroinflammation.

Note: We do use YouTube Video’s under the “Fair Use” Act under the Copyright Law:

“Fair use is a doctrine in the United States copyright law codified in Section 107 of the Copyright Act of 1976.¹ It provides for the legal, non-licensed citation or incorporation of copyrighted material in another author’s work without requiring permission from the rights holders, such as for commentary, criticism, news reporting, research, teaching or scholarship.⁰¹ The U.S. Copyright Office Fair Use Index should prove helpful in understanding what courts have to date considered to be fair or not fair but it is not a substitute for legal advice.²“